This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Abiomed Balance Sheet Health
Financial Health criteria checks 6/6
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -62.2x |
Cash | US$820.37m |
Equity | US$1.54b |
Total liabilities | US$156.76m |
Total assets | US$1.70b |
Recent financial health updates
Is Abiomed (NASDAQ:ABMD) A Risky Investment?
Mar 17These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely
Dec 14Recent updates
Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward
Oct 24Abiomed's Impella low profile sheath gets FDA clearance
Oct 17Abiomed: Correction Offers Good Buying Opportunity
Sep 28U.S. FDA gives two approvals to Abiomed Impella heart pumps
Sep 16What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?
Sep 13Abiomed FQ1 2023 Earnings Preview
Aug 03Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled
Jul 11Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages
May 17Is Abiomed (NASDAQ:ABMD) A Risky Investment?
Mar 17Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk
Jan 24The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing
Jan 04These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely
Dec 14Abiomed: Impella Will Continue To Drive Revenue Growth
Sep 10Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return
Sep 01Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
Jul 13At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?
Jul 08DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue
Jun 08Abiomed acquires preCARDIA a company targeting acute heart failure
Jun 01Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today
May 16Boston Scientific’s new clinical trial can impact Abiomed: Raymond James
May 06Abiomed FQ4 2021 Earnings Preview
Apr 28Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?
Apr 02Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 12Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?
Feb 18Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Jan 31Financial Position Analysis
Short Term Liabilities: ABMD's short term assets ($1.1B) exceed its short term liabilities ($134.1M).
Long Term Liabilities: ABMD's short term assets ($1.1B) exceed its long term liabilities ($22.7M).
Debt to Equity History and Analysis
Debt Level: ABMD is debt free.
Reducing Debt: ABMD had no debt 5 years ago.
Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.